Recommendation of the President – Chenodeoxycholic acid Leadiant (chenodeoxycholic acid)

On 10 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 149/2024 on the advisability of granting approval for the reimbursement of the medicinal product Chenodeoxycholic acid Leadiant (chenodeoxycholic acid) for the indication: cerebral yellowing disease

Publication in Public Information Bulletin (BIP) >>